Please login to the form below

Not currently logged in
Email:
Password:

Biotech and vaccines focus for sanofi-aventis

French drugs maker sanofi-aventis has announced that it plans to shift its emphasis to biotechnology and vaccine production

French drugs maker sanofi-aventis (S-A) has announced that by 2014 it plans to shift its emphasis to biotechnology and vaccine production in France, and away from the chemical production of drugs.

The company is presenting employees with its plans to invest €150m in the transfer, which will entail training programmes and the creation of the group's third largest European vaccine production site.

The company said the move reflects its shift in business from producing drugs through synthetic chemistry following patent expirations of several key drugs.

The new activities will create jobs locally, the company said.

31st March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics